7th Dec 2015 13:01
SUMMIT (Alliance News) - Celgene Corp and AstraZeneca PLC said they have initiated the FUSION clinical development program of durvalumab or MEDI4736, an investigational human monoclonal antibody directed against programmed cell death ligand 1 or PD-L1 in hematologic disorders.
The FUSION program is part of a strategic collaboration by Celgene with AstraZeneca and its global biologics research and development arm MedImmune, to develop and commercialize durvalumab across a range of blood cancers including non-Hodgkin's lymphoma, myelodysplastic syndromes and multiple myeloma.
The program will start with four studies of durvalumab and combination therapies across multiple hematologic disorders.
Copyright RTT News/dpa-AFX
Related Shares:
Astrazeneca